Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00300430 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,911
- Enrollment target
NCT00300430 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 1,911 participants.
The verdict
NCT00300430, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,911 participants
- Enrollment target
Study Summary
The primary purpose of this study is to test the safety and the effects of using an investigational drug regimen; once daily ABT-335 (Investigational drug) administered in combination with once daily atorvastatin calcium, rosuvastatin calcium or simvastatin in patients with abnormal lipid levels in the blood.
Interventions
- DRUG ABT-335 and rosuvastatin calcium
- DRUG ABT-335 and atorvastatin calcium
- DRUG ABT-335 and simvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,911 participants |
| Start Date | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00300430
The ClinicalTrials.gov registry entry for NCT00300430 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,911 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ABT-335 and rosuvastatin calcium is the first listed.
NCT00300430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00300430 about?
NCT00300430 is a clinical study titled "Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.". The primary purpose of this study is to test the safety and the effects of using an investigational drug regimen; once daily ABT-335 (Investigational drug) administered in combination with once daily atorvastatin calcium, rosuvastatin calcium or simvastatin in patients with abnormal lipid levels in ...
What is the current status of trial NCT00300430?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,911 participants. The study started on 2006-09.
What interventions are being tested in trial NCT00300430?
The interventions under investigation include: ABT-335 and rosuvastatin calcium (DRUG), ABT-335 and atorvastatin calcium (DRUG), ABT-335 and simvastatin (DRUG).
Who is sponsoring clinical trial NCT00300430?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.